immune‑cell activator

Ichnos Glenmark Innovation (IGI) advances solid‑tumor candidate ISB 2301 after completing pre‑clinical development

Glenmark Pharmaceuticals’ innovation arm, Ichnos Glenmark Innovation (IGI), has completed pre‑clinical development of ISB 2301, a next‑generation multispecific antibody for…